Coherus to present data from a phase 1 dose expansion study of chs-114, a cytolytic antibody targeting chemokine receptor 8 (ccr8), at the 2025 american association for cancer research (aacr) annual meeting

Redwood city, calif., march 25, 2025 (globe newswire) -- coherus biosciences, inc. (“coherus,” nasdaq: chrs), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing phase 1 clinical trial evaluating chs-114, a selective, cytolytic anti-ccr8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (hnscc), has been selected for a poster presentation at the upcoming 2025 aacr annual meeting, being held april 25-30, 2025, at mccormick place convention center in chicago, illinois.
CHSCL Ratings Summary
CHSCL Quant Ranking